Wegovy injection contains semaglutide and is prescribed for weight management alongside diet and activity support. The standard escalation reaches 2.4 mg weekly; the current UK licence also allows 7.2 mg for some adults with obesity when clinically needed.
Understand the formulation being discussed
Wegovy injection is a once-weekly form of semaglutide, a GLP-1 receptor agonist that supports appetite regulation. It is a prescription medicine used alongside dietary and physical activity changes. Semaglutide also exists in other products, including Wegovy tablets. Sharing an ingredient does not make the products interchangeable: route, dose, instructions and authorised uses need to be checked separately.
This hub focuses on adult weight management. The injection also has an adolescent weight-management indication with specific criteria, but adult price comparisons and adult high-dose schedules should not be applied to children. A service assessing an adult should still consider the whole medical history rather than treating a BMI entry as a prescription approval.
Sources: NHS: Semaglutide: uses, side effects and precautions; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics
Put trial results in their proper context
STEP 1 studied 2.4 mg semaglutide in 1,961 adults with overweight or obesity who did not have diabetes. At 68 weeks, mean weight change was a reduction of 14.9% with semaglutide and 2.4% with placebo, alongside lifestyle support. Some people lost more, some less, and some stopped treatment. A trial average cannot predict your individual trajectory.
Separate studies can answer different questions. STEP 2 enrolled adults with type 2 diabetes and reported a smaller average reduction with the same 2.4 mg dose. This illustrates why a headline percentage needs a population, dose, duration and analysis attached to it. Comparing isolated percentages from different studies gives a misleading sense of precision.
Sources: New England Journal of Medicine: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity; The Lancet / PubMed: STEP 2: Semaglutide 2.4 mg in adults with overweight or obesity and type 2 diabetes
The current dose range includes an important update
Older information may describe 2.4 mg as the highest UK dose. The current licence also permits 7.2 mg weekly for weight management in some adults with obesity, after at least four weeks on 2.4 mg. This is a clinician-led option, not a default next step for everyone. Adolescents should not receive doses above 2.4 mg under the weight-management schedule.
The STEP UP trial compared 7.2 mg, 2.4 mg and placebo. The treatment-policy analysis reported mean reductions of 18.7%, 15.6% and 3.9% at 72 weeks. Any possible additional benefit must be considered with tolerability and the individual's circumstances. Check whether a quoted 7.2 mg supply uses the relevant single-dose device or multiple 2.4 mg injections, because pack counts and instructions differ.
Sources: MHRA: MHRA approves up to 7.2 mg semaglutide for adults with obesity; The Lancet Diabetes & Endocrinology / PubMed: STEP UP: Once-weekly semaglutide 7.2 mg in adults with obesity; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics
Look beyond a weekly number on the scales
A useful review includes whether the treatment is manageable, whether you can maintain adequate food and fluid intake, and whether symptoms interfere with work, sleep or activity. Track weight in a consistent way and discuss the trend rather than treating each measurement as a verdict. Agree which health outcomes matter to you and how the service will reassess progress.
Wegovy is not simply a short course ending when a particular number appears. In STEP 4, people who switched from semaglutide to placebo after an initial treatment period regained weight on average, whereas those continuing treatment lost more. That finding supports discussing maintenance early. It does not establish that every person must remain on the same medicine indefinitely.
Sources: NICE: Overweight and obesity management: medicines and surgery; JAMA / PubMed: STEP 4: Continued semaglutide versus placebo for weight loss maintenance
Digestive effects and urgent warning signs
Nausea, vomiting, diarrhoea and constipation are among the recognised adverse effects. Tell your prescriber when symptoms persist or make normal eating and drinking difficult. Seek urgent assessment for severe persistent abdominal pain, particularly if it spreads to the back. Sudden loss of vision, especially in one eye, requires urgent eye casualty or A&E assessment; the MHRA recognises NAION as a very rare semaglutide side effect.
Tell all treating clinicians that you take semaglutide, including before general anaesthesia or deep sedation. Discuss pregnancy plans in advance: semaglutide should be stopped at least two months before a planned pregnancy. These precautions apply even if the medicine comes from an online private provider rather than your usual GP.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet; MHRA: MHRA updates semaglutide guidance on very rare NAION; MHRA: GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedation
Compare the right product and the support around it
Confirm that the quote is for the injection, the prescribed strength and the full intended supply. A starter-dose offer does not tell you the cost of maintenance. If a service lists 7.2 mg, ask precisely what it dispenses and how the total covers the prescribed schedule. Do not convert pens, strengths or injection counts yourself.
NICE recommendations for NHS semaglutide weight management include a specialist-service pathway and a maximum two-year treatment period under that guidance. Those funding conditions are distinct from private prescribing decisions and the product licence. For either route, establish who reviews treatment, how you obtain help between appointments, and what happens when a prescription is delayed or treatment is stopped.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics; NICE: TA875: Semaglutide for managing overweight and obesity; General Pharmaceutical Council and UK health organisations: How to keep safe when getting medicines or treatment online
Compare prices for your prescribed dose
The usual escalation uses 0.25, 0.5, 1 and 1.7 mg for four weeks each before 2.4 mg. For eligible adults with obesity, a prescriber may consider 7.2 mg after at least four weeks on 2.4 mg. Device and pack quantities must be checked.
These are first-order price observations, not prescribing recommendations. Repeat costs and additional fees may differ.
Questions, answered.
Is 7.2 mg appropriate for everyone taking Wegovy?
No. It is an option for some adults with obesity, subject to the licensed criteria and a prescriber's assessment. It is not the adolescent dose or an automatic escalation.
Sources: MHRA: MHRA approves up to 7.2 mg semaglutide for adults with obesity
Can I compare the tablet and injection milligram numbers?
No. Absorption differs between oral and injected semaglutide. A numerically larger tablet dose does not mean a proportionally stronger effect.
What should a repeat review cover?
Bring the dose history, weight trend, side effects, other medicines and practical difficulties. Ask the prescriber to explain the continuation plan and when it will next be reviewed.
Sources: NICE: Overweight and obesity management: medicines and surgery
Sources & further reading
Original sources for this guide. Source checks are not independent clinical review.
- Semaglutide: uses, side effects and precautionsNHS · Accessed 19 November 2026
- Wegovy FlexTouch: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- Wegovy FlexTouch: patient information leafletNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- STEP 1: Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine · Accessed 19 November 2026
- STEP 2: Semaglutide 2.4 mg in adults with overweight or obesity and type 2 diabetesThe Lancet / PubMed · Accessed 19 November 2026
- MHRA approves up to 7.2 mg semaglutide for adults with obesityMHRA · Accessed 19 November 2026
- STEP UP: Once-weekly semaglutide 7.2 mg in adults with obesityThe Lancet Diabetes & Endocrinology / PubMed · Accessed 19 November 2026
- Overweight and obesity management: medicines and surgeryNICE · Accessed 19 November 2026
- STEP 4: Continued semaglutide versus placebo for weight loss maintenanceJAMA / PubMed · Accessed 19 November 2026
- MHRA updates semaglutide guidance on very rare NAIONMHRA · Accessed 19 November 2026
- GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedationMHRA · Accessed 19 November 2026
- TA875: Semaglutide for managing overweight and obesityNICE · Accessed 19 November 2026
- How to keep safe when getting medicines or treatment onlineGeneral Pharmaceutical Council and UK health organisations · Accessed 19 November 2026
- Wegovy tablets: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
